Abstract:Resistance to therapy is a persistent problem that leads to mortality in breast cancer, particularly triple-negative breast cancer (TNBC). MiRNAs have become a focus of investigation as tissue-specific regulators of gene networks related to drug resistance. Circulating miRNAs are readily accessible non-invasive potential biomarkers for TNBC diagnosis, prognosis, and drug-response. Our aim was to use systems biology, meta-analysis, and network approaches to delineate the drug resistance pathways and clinical outcomes associated with circulating miRNAs in TNBC patients. MiRNA expression analysis was used to investigate differentially regulated circulating miRNAs in TNBC patients, and integrated pathway regulation, gene ontology, and pharmacogenomic network analyses were used to identify target genes, miRNAs, and drug interaction networks. Herein, we identified significant differentially expressed circulating miRNAs in TNBC patients (miR-19a/b-3p, miR-25-3p, miR-22-3p, miR-210-3p, miR-93-5p, and miR-199a-3p) that regulate several molecular pathways (PAM (PI3K/Akt/mTOR), HIF-1, TNF, FoxO, Wnt, and JAK/STAT, PD-1/PD-L1 pathways and EGFR tyrosine kinase inhibitor resistance (TKIs)) involved in drug resistance. Through meta-analysis, we demonstrated an association of upregulated miR-93, miR-210, miR-19a, and miR-19b with poor overall survival outcomes in TNBC patients. These results identify miRNA-regulated mechanisms of drug resistance and potential targets for combination with chemotherapy to overcome drug resistance in TNBC. We demonstrate that integrated analysis of multi-dimensional data can unravel mechanisms of drug-resistance related to circulating miRNAs, particularly in TNBC. These circulating miRNAs may be useful as markers of drug response and resistance in the guidance of personalized medicine for TNBC.

What problem does this paper attempt to address?

This paper aims to solve the problem of treatment resistance in triple - negative breast cancer (TNBC). Specifically, the study focused on the abnormal expression of circulating microRNAs (miRNAs) in TNBC patients and their relationship with drug response. Through target gene network analysis and meta - analysis methods, researchers hope to reveal the role of these circulating miRNAs in drug - resistance pathways and explore their potential value as clinical markers, especially in guiding personalized treatment. ### Research Background - **Treatment Resistance**: Treatment resistance is a major problem leading to the death of breast cancer patients, especially in triple - negative breast cancer (TNBC). miRNAs, as tissue - specific gene network regulators, have become the focus of research. - **Circulating miRNAs**: Circulating miRNAs are considered potential biomarkers for TNBC diagnosis, prognosis, and drug response due to their non - invasive and easy - to - detect characteristics. ### Research Objectives - **Systems Biology and Meta - analysis**: Use systems biology, meta - analysis, and network analysis methods to identify circulating miRNAs related to drug resistance in TNBC patients and their clinical outcomes. - **miRNA Expression Analysis**: Through miRNA expression analysis, study the differentially expressed circulating miRNAs in breast cancer patients of different subtypes, especially TNBC. - **Pathway and Gene Ontology Analysis**: Combine pathway regulation, gene ontology, and pharmacogenomics network analysis to identify target genes, miRNAs, and drug - interaction networks. ### Main Findings - **Significantly Differentially Expressed miRNAs**: The study found that miR - 19a/b - 3p, miR - 25 - 3p, miR - 22 - 3p, miR - 210 - 3p, miR - 93 - 5p, and miR - 199a - 3p were significantly differentially expressed in TNBC patients. - **Related Molecular Pathways**: These miRNAs regulate multiple molecular pathways related to drug resistance, such as the PI3K/Akt/mTOR, HIF - 1, TNF, FoxO, Wnt, JAK/STAT, PD - 1/PD - L1 pathways, and EGFR tyrosine kinase inhibitor resistance (TKIs). - **Survival Analysis**: Through meta - analysis, the study found that up - regulated miR - 93, miR - 210, miR - 19a, and miR - 19b were associated with poor overall survival rates in TNBC patients. ### Conclusions - **miRNA Regulatory Mechanisms**: The study revealed the miRNA - regulated drug - resistance mechanisms and identified potential targets that may be used in combination with chemotherapy. - **Personalized Medicine**: These circulating miRNAs may serve as markers of drug response and resistance, helping to guide personalized treatment of TNBC. Through comprehensive analysis of multi - dimensional data, this study provides a new perspective on revealing the drug - resistance mechanisms related to circulating miRNAs, especially in TNBC. This provides a theoretical basis for further research on combination therapies of specific miRNA targets.

Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis

Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis

MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer.

MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer

Identification of miRNAs and related hub genes associated with the triple negative breast cancer using integrated bioinformatics analysis and in vitro approach

Bioinformatics Identification of Dysregulated Micrornas in Triple Negative Breast Cancer Based on Microrna Expression Profiling.

Identification of Dysregulated Micrornas in Triple-Negative Breast Cancer (Review).

The regulation of microRNAs on chemoresistance in triple-negative breast cancer: a recent update

MicroRNA-Based Discovery of Biomarkers, Therapeutic Targets, and Repositioning Drugs for Breast Cancer

Exploring miRNA‐target gene profiles associated with drug resistance in patients with breast cancer receiving neoadjuvant chemotherapy

Gene Expression Profile Analysis to Discover Molecular Signatures for Early Diagnosis and Therapies of Triple-Negative Breast Cancer

In Silico Analysis of Publicly Available Transcriptomic Data for the Identification of Triple-Negative Breast Cancer-Specific Biomarkers

Mechanism of miRNAs and miRNA-mRNA Regulatory Networks in Modulating Drug Resistance in HER2-Positive Breast Cancer: An Integrative Bioinformatics Approach

Model-Based Integration Analysis Revealed Presence of Novel Prognostic Mirna Targets and Important Cancer Driver Genes in Triple-Negative Breast Cancers.

Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic Vulnerabilities

Reawakening the Master Switches in Triple-Negative Breast Cancer: A Strategic Blueprint for Confronting Metastasis and Chemoresistance via MicroRNA-200/205: a systematic review.

Identification of Dysregulated Micrornas Associated with Diagnosis and Prognosis in Triple‑negative Breast Cancer: an in Silico Study.

Secreted Non-Coding RNAs: Functional Impact on the Tumor Microenvironment and Clinical Relevance in Triple-Negative Breast Cancer

Identification of Chemoresistance-Associated Mirnas in Breast Cancer

Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review

Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targets